×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Compounders Sue FDA Over Semaglutide Shortage Decision
CVS Caremark Faces Lawsuit Over Dropping Zepbound
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
EU Recommends Wegovy® Label Update for Heart Failure in Obesity
FDA Approves Wegovy for MASH Treatment
FDA Declares Semaglutide Shortage Resolved, Raising Concerns Over Compounded Versions
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Novo Nordisk Ends Partnership with Hims & Hers Over Safety Concerns
Novo Nordisk Expands $499 Wegovy® Offer to Retail Pharmacies
Novo Nordisk Launches $499 Cash Program for Wegovy, Matching Eli Lilly’s Zepbound Pricing
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novo Nordisk's Stance on Semaglutide for Cosmetic Use
Public Perception of Obesity and Weight-Loss Drugs
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
Semaglutide 7.2 mg Demonstrates Greater Weight Loss but Faces Market Challenges
Sustained Weight Loss and Cardiovascular Risk Reduction with Wegovy
The Economic Impact of Ozempic on Denmark
The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?
Page 1 of 2
1
2
Articles
The Economic Impact of Ozempic on Denmark
Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management
Understanding the Link Between Type 2 Diabetes and Chronic Kidney Disease
New York Takes a Bold Step to Tackle Insulin Affordability
Epigenetic Clues to Heart Risk in Type 2 Diabetes
Navigating Prior Authorization for Type 2 Diabetes Treatments
How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Viewing Type 2 Diabetes as a Vascular Disease
Public Perception of Obesity and Weight-Loss Drugs
Diabetes and Heart Health: A Crucial Connection
The Power of Exercise and Music in Managing Type 2 Diabetes
FDA Clears Dexcom's Stelo, First Over-the-Counter Glucose Biosensor for Type 2 Diabetes Management
Empowering Type 2 Diabetes Management: Dexcom's CGM Innovations and Clinical Breakthroughs
Successfully Completed: Diabetes – A Global Challenge
The Future of Type 2 Diabetes and Obesity Care: The Role of DNA Sequencing
Understanding Obesity: Beyond the Scale
New Research Reveals the Hidden Complexity of Insulin Resistance
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results
September 2025
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
August 2025
FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Top Subjects
Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
